Clinical Trials Browser

Carcinoma, Renal Cell, Digestive System Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Adenocarcinoma, Clear Cell, Rhabdoid Tumor

NCT02989064 2026-02-04

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Phase 1 Completed

10 enrolled

DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

51 enrolled

Dermatologic

Melanoma

NCT01970358 2025-12-29

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Phase 1 Completed

15 enrolled 8 charts

Dermatologic

Melanoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT05668585 2025-11-21

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Phase 1 Completed

89 enrolled

Dermatologic

Melanoma

NCT05293496 2025-10-14

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Liver Neoplasms, Melanoma, Carcinoma, Pancreatic Ductal, Prostatic Neoplasms, Castration-Resistant

NCT04812470 2025-09-22

HAITILS

Phase 1 Completed

8 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03708328 2025-08-20

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1 Completed

134 enrolled 37 charts

DermatologicGastrointestinalThoracic

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Small Cell Lung Carcinoma

NCT01863108 2025-08-13

GeniusVac-Mel4

Phase 1 Completed

9 enrolled

Dermatologic

Melanoma

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Phase 1 Completed

146 enrolled 38 charts

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT04217473 2025-08-07

TUNINTIL

Phase 1 Completed

17 enrolled

Dermatologic

Melanoma

NCT01239134 2025-08-03

TRX518-001

Phase 1 Completed

10 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT02680184 2025-07-04

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Phase 1 Completed

199 enrolled

Dermatologic

Melanoma

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

272 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Phase 1 Completed

185 enrolled

BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02836795 2025-06-08

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

DermatologicGenitourinary

Melanoma, Urologic Neoplasms

NCT02029729 2025-05-29

DISCOVER

Phase 1 Completed

11 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Recurrence

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Phase 1 Completed

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1 Completed

41 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT00386906 2025-05-07

Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma

Phase 1 Completed

38 enrolled

Dermatologic

Eye Diseases, Melanoma

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

13 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT04291079 2025-04-29

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Phase 1 Completed

112 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1 Completed

58 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Phase 1 Completed

64 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

NCT03761017 2025-03-06

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Phase 1 Completed

162 enrolled

DermatologicGastrointestinal

Melanoma, Colorectal Neoplasms

NCT03475134 2025-02-11

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Phase 1 Completed

18 enrolled

Dermatologic

Melanoma

NCT03665597 2025-02-10

KEYNOTE-555

Phase 1 Completed

138 enrolled 34 charts 2 FDA

Dermatologic

Melanoma

NCT06469138 2025-01-29

8479217

Phase 1 Completed

6 enrolled 17 charts

CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed

18 enrolled

Dermatologic

Melanoma

NCT01946789 2025-01-22

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Phase 1 Completed

26 enrolled 22 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Phase 1 Completed

91 enrolled

Dermatologic

Melanoma

NCT03092453 2024-12-24

Dendritic Cell Vaccination in Patients With Advanced Melanoma

Phase 1 Completed

5 enrolled 10 charts

Dermatologic

Melanoma

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05169957 2024-11-05

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Phase 1 Completed

2 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04096638 2024-10-31

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Phase 1 Completed

61 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT03875079 2024-10-03

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

Phase 1 Completed

83 enrolled

Dermatologic

Melanoma

NCT02791334 2024-09-27

PACT

Phase 1 Completed

164 enrolled

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Completed

37 enrolled 25 charts

Dermatologic

Melanoma

NCT03538314 2024-08-22

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Phase 1 Completed

30 enrolled

Dermatologic

Melanoma

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

96 enrolled

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Clinical Trials

A Study of DF6002 Alone and in Combination With Nivolumab

Study of DF6215 in Patients With Advanced Solid Tumors

Lipo-MERIT

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

HAITILS

ARC-12

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

GeniusVac-Mel4

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

TUNINTIL

TRX518-001

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

DISCOVER

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

MGD019 DART® Protein in Unresectable/Metastatic Cancer

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

KEYNOTE-555

8479217

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Dendritic Cell Vaccination in Patients With Advanced Melanoma

IVY

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

PACT

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors